World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
82
Citations
43148
World Ranking
15855
National Ranking
619

Mario Mandalà publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Mario Mandalà sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 476 publications — 54th percentile

54% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Mario Mandalà D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Mario Mandalà sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 82 D-Index — 21st percentile

21% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Mario Mandalà is affiliated with the European Institute of Oncology in Italy and has a significant body of work primarily concentrated in Medicine and Biochemistry, Genetics and Molecular Biology. Their research covers various subfields including Oncology, Molecular Biology, Immunology, Pulmonary and Respiratory Medicine, and Organic Chemistry.

The researcher has contributed extensively to topics such as:

  • Melanoma and MAPK Pathways
  • Cutaneous Melanoma Detection and Management
  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Colorectal Cancer Treatments and Studies
  • Click Chemistry and Applications

Notable recent papers authored or co-authored by Mandalà include:

  • Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial (2020) published in The Lancet Oncology
  • Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo (2020) published in JAMA Oncology
  • Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma (2020) published in New England Journal of Medicine
  • Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial (2021) published in The Lancet Oncology
  • Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline (2023) published in Annals of Oncology

Frequent collaborators in their work include:

  • Paolo A. Ascierto
  • Caroline Robert
  • Dirk Schadendorf
  • Reinhard Dummer
  • Ana Arance

Mario Mandalà's research appears regularly in several publication venues, including:

  • Annals of Oncology
  • European Journal of Cancer
  • Journal of Clinical Oncology
  • The Lancet Oncology
  • Journal for ImmunoTherapy of Cancer

This body of work reflects a focus on cancer treatment and immunotherapy, with detailed investigations into melanoma management and immune-related cancer therapies. Their affiliation with a major oncology institute complements this specialized research area, integrating clinical and molecular approaches to cancer study.

Best Publications

  • Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

    James Larkin;Paolo A. Ascierto;Brigitte Dréno;Victoria Atkinson

  • Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

    Jeffrey Weber;Mario Mandala;Michele Del Vecchio;Helen J. Gogas

  • Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

    G.V. Long;D. Stroyakovskiy;H. Gogas;E. Levchenko

  • Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

    Alexander M.M. Eggermont;Christian U. Blank;Mario Mandala;Georgina V. Long

  • Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial

    Charles S. Fuchs;Toshihiko Doi;Raymond W. Jang;Raymond W. Jang;Kei Muro

  • Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

    Georgina V. Long;Georgina V. Long;Daniil Stroyakovskiy;Helen Gogas;Evgeny Levchenko

  • Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

    G. V. Long;A. Hauschild;M. Santinami;V. Atkinson

  • Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    R. Labianca;B. Nordlinger;G. D. Beretta;S. Mosconi

  • Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

    Kohei Shitara;Mustafa Özgüroğlu;Yung-Jue Bang;Maria Di Bartolomeo

  • Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

    Caroline Robert;Jean J Grob;Daniil Stroyakovskiy;Boguslawa Karaszewska

  • Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.

    Paolo A Ascierto;Grant A McArthur;Grant A McArthur;Brigitte Dréno;Victoria Atkinson

  • Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

    Reinhard Dummer;Paolo A Ascierto;Helen J Gogas;Ana Arance

  • Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study

    Giancarlo Agnelli;Gualberto Gussoni;Carlo Bianchini;Melina Verso

  • International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer

    D Farge;P Debourdeau;M Beckers;C Baglin

  • Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

    G. V. Long;K. T. Flaherty;D. Stroyakovskiy;H. Gogas

  • Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines.

    M. Mandalà;A. Falanga;F. Roila

  • Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

    Reinhard Dummer;Paolo A Ascierto;Helen J Gogas;Ana Arance

  • 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.

    Dominique Farge;Dominique Farge;Corinne Frere;Jean M Connors;Cihan Ay

  • Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

    Reinhard Dummer;Dirk Schadendorf;Paolo A Ascierto;Ana Arance

  • Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.

    Paolo A. Ascierto;Michele Del Vecchio;Mario Mandalá;Helen Gogas

Frequent Co-Authors

Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Georgina V. Long
Georgina V. Long University of Sydney
Caroline Robert
Caroline Robert University of Paris-Saclay
James Larkin
James Larkin Royal Marsden NHS Foundation Trust
Sandro Barni
Sandro Barni Mario Negri Institute for Pharmacological Research
Reinhard Dummer
Reinhard Dummer University of Zurich
Claus Garbe
Claus Garbe University of Tübingen
Vanna Chiarion-Sileni
Vanna Chiarion-Sileni European Institute of Oncology
Michele Maio
Michele Maio University of Siena

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring careers in Medicine doesn’t always mean following a traditional MD route. There are a variety of online dnp programs without dissertation that allow working nurses to advance their credentials with more flexibility and less intensive research requirements. These programs are ideal for those looking to move into leadership, advanced clinical roles, or academia while balancing work and personal commitments.

For career changers or those eager to enter the healthcare workforce quickly, an accelerated lpn program provides a fast-track pathway into practical nursing. These online offerings are structured to deliver essential skills in a reduced timeframe, helping students secure stable, in-demand jobs faster.

Specializations are another way to boost your opportunities. With the rise of mental health awareness, online pmhnp programs (Psychiatric Mental Health Nurse Practitioner) enable nurses to focus on advanced mental health practice.

If you’re interested in leadership or the business side of healthcare, earning a healthcare administration degree online can open doors to management and executive roles across hospitals and clinics.

Best Scientists Citing Mario Mandalà

Trending Scientists

Recently Published Articles